 ANTICIPATED BENEFITS ASSOCIATED WITH THE PROTOCOL value or desired outcome advantage TO HUMAN RESEARCH PARTICIPANTS AND SOCIETY medical, psychosocial, altruistic Anticipated direct benefits of this study include the improvement in appetitebehavior and growth amongst the patients receiving cyproheptadine. These benefits may also be present in group abstaining from cyproheptadine due to standard education that is given to all groups. However, the investigators anticipate these benefits to be significantly lower in this group as compared to patients who are on cyproheptadine. Long-term benefits include the creation and utilization of a protocol outlining the use of cyproheptadine in feeding team patients. The results of this study will also address the side effect profile of cyproheptadine in this population. It may also further investigators knowledge of the treatment approaches that are most successful, allowing physicians to develop standardized care to better serve these patients and their families. 